Literature DB >> 26985310

Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome.

David L Wilson1, Isabel Meininger2, Zack Strater1, Stephanie Steiner1, Frederick Tomlin1, Julia Wu1, Haya Jamali1, Daniel Krappmann2, Marion G Götz1.   

Abstract

This research explores the first design and synthesis of macrocyclic peptide aldehydes as potent inhibitors of the 20S proteasome. Two novel macrocyclic peptide aldehydes based on the ring-size of the macrocyclic natural product TMC-95 were prepared and evaluated as inhibitors of the 20S proteasome. Both compounds inhibited in the low nanomolar range and proved to be selective for the proteasome over other serine and cysteine proteases, particularly when compared to linear analogues with similar amino acid sequences. In HeLa cells, both macrocycles efficiently inhibited activation of nuclear factor-κB (NF-κB) transcription factor by blocking proteasomal degradation of the inhibitor protein IκBα after cytokine stimulation. Due to their covalent mechanism of binding these compounds represent a 1000-fold increase in inhibitory potency over previously reported noncovalently binding TMC-95 analogues. Molecular modeling of the macrocyclic peptides confirms the preference of the large S3 pocket for large, hydrophobic residues and the ability to exploit this to improve selectivity of proteasome inhibitors.

Entities:  

Keywords:  Proteasome; aldehyde; inhibitor; macrocycle; multiple myeloma

Year:  2016        PMID: 26985310      PMCID: PMC4789680          DOI: 10.1021/acsmedchemlett.5b00401

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

1.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.

Authors:  E Oda; R Ohki; H Murasawa; J Nemoto; T Shibue; T Yamashita; T Tokino; T Taniguchi; N Tanaka
Journal:  Science       Date:  2000-05-12       Impact factor: 47.728

Review 2.  The 26S proteasome: a molecular machine designed for controlled proteolysis.

Authors:  D Voges; P Zwickl; W Baumeister
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

3.  Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor.

Authors:  M Groll; Y Koguchi; R Huber; J Kohno
Journal:  J Mol Biol       Date:  2001-08-17       Impact factor: 5.469

Review 4.  Protein degradation and protection against misfolded or damaged proteins.

Authors:  Alfred L Goldberg
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

5.  The core structure of TMC-95A is a promising lead for reversible proteasome inhibition.

Authors:  Markus Kaiser; Michael Groll; Christian Renner; Robert Huber; Luis Moroder
Journal:  Angew Chem Int Ed Engl       Date:  2002-03-01       Impact factor: 15.336

Review 6.  Protein degradation by the ubiquitin-proteasome pathway in normal and disease states.

Authors:  Stewart H Lecker; Alfred L Goldberg; William E Mitch
Journal:  J Am Soc Nephrol       Date:  2006-05-31       Impact factor: 10.121

Review 7.  The exploration of macrocycles for drug discovery--an underexploited structural class.

Authors:  Edward M Driggers; Stephen P Hale; Jinbo Lee; Nicholas K Terrett
Journal:  Nat Rev Drug Discov       Date:  2008-07       Impact factor: 84.694

8.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Authors:  T Hideshima; P Richardson; D Chauhan; V J Palombella; P J Elliott; J Adams; K C Anderson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

9.  TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors.

Authors:  Markus Kaiser; Alexander G Milbradt; Carlo Siciliano; Irmgard Assfalg-Machleidt; Werner Machleidt; Michael Groll; Christian Renner; Luis Moroder
Journal:  Chem Biodivers       Date:  2004-01       Impact factor: 2.408

10.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

Authors:  J Adams; M Behnke; S Chen; A A Cruickshank; L R Dick; L Grenier; J M Klunder; Y T Ma; L Plamondon; R L Stein
Journal:  Bioorg Med Chem Lett       Date:  1998-02-17       Impact factor: 2.823

View more
  2 in total

1.  Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors.

Authors:  Grace E Hubbell; Jetze J Tepe
Journal:  RSC Chem Biol       Date:  2020-09-16

Review 2.  Recent Advances in Macrocyclic Drugs and Microwave-Assisted and/or Solid-Supported Synthesis of Macrocycles.

Authors:  Dianqing Sun
Journal:  Molecules       Date:  2022-02-02       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.